Key Takeaways Lilly stock moved above its 50-day SMA after a rebound from post-Q2 declines.ATTAIN-2 study success for oral obesity drug eased earlier investor concerns.Mounjaro and Zepbound now drive about half of Lilly's revenues on rising demand.Eli Lilly and Company’s (LLY) stock moved past the 50-day Simple Moving Average (SMA) last week after trading below the same since the end of July. When a stock's price moves above its 50-day SMA, it signals a potential bullish trend. Image Source: Zacks Investmen ...

BitMine Immersion Technologies (NYSE: BMNR) recently published its latest figures: a total holdings of $10.77 billion in crypto, cash, and strategic investments as of September 14, 2025. BitMine’s reserves include 2,151,676 ETH (valued at $4,632 per ETH), 192 Bitcoin, $214 million in Eightco “moonshot” equity stakes, and $569 million in cash.The company ranks as the world’s largest Ethereum corporate treasury, and is currently second to Strategy Inc. (formerly MicroStrategy) in overall crypto holdings, with ...

格拉斯哥大学代谢医学教授Naveed Sattar指出， 这种"渐进式"的益处在临床上仍具重要意义，特别是考虑到礼来高剂量替西帕肽在某 些地区的价格已大幅上涨。 他认为： "如果定价具有竞争力，7.2毫克剂量的司美格鲁肽将成为一个更实惠的选择。" 诺和诺德的司美格鲁肽在临床试验中将剂量增至三倍后，患者平均减重达19%，超过标准剂量16%。尽管效果有所提升，但仍逊于竞争对 手礼来的替西帕肽（22.5%）。高剂量方案可能为患者提供更具成本效益的选择，但同时伴随着更高的副作用发生率。 诺和诺德公司日前公布了一项临床试验结果， 其备受关注的司美格鲁肽（Semaglutide）在将剂量提高至三倍后，显示出更显著的减重 效果。 司美格鲁肽是诺和诺德的王牌产品，以减重药Wegovy和糖尿病药物Ozempic的品牌进行销售。在两项最新的三期临床试验中，研究人 员测试了 7.2毫克 的司美格鲁肽剂量，而目前已获批的最高剂量为 2.4毫克 。 在两项试验中规模较大的一项中， 患者在72周后平均减重19%。 作为对比，使用2.4毫克标准剂量的患者平均减重16%，而安慰剂组仅 减重4%。 然而，这一数据仍未超越市场领导者礼来的替西帕 ...

Site of an Eastman Chemical plant in Kingsport, Tennessee. Eastman is one of a few companies whose insiders have recently purchased their own stock. (Photo by Earl Neikirk/For The Washington Post via Getty Images)The Washington Post via Getty ImagesThis column frequently tracks insider buys by companies’ chief executives. Lately, they are scarce.Executives normally sell more shares than they buy because their cup is periodically refilled via stock-option grants. Over the past 21 years, according to Gurufocu ...

Eli Lilly and Co. (NYSE:LLY) is one of the best defensive stocks to buy, according to Steve Cohen. On September 9, the company announced the launch of an artificial intelligence and machine learning platform. Eli Lilly and Company (LLY) Unveils AI Platform to Enhance Drug Discovery Pixabay/Public Domain TuneLab is the platform that consists of AI models and proprietary data obtained at a cost of more than $1 billion. The platform is designed to provide biotech companies with all the necessary models tra ...

在两项试验中规模较大的一项中，患者在72周后平均减重19%。作为对比，使用2.4毫克标准剂量的患者平均减重16%，而安慰剂组仅减重4%。 然而，这一数据仍未超越市场领导者礼来的替西帕肽（tirzepatide）。礼来的该款药物以Zepbound和Mounjaro的品牌销售，其最高批准剂量的试验 结果显示，平均减重效果高达22.5%。 司美格鲁肽是诺和诺德的王牌产品，以减重药Wegovy和糖尿病药物Ozempic的品牌进行销售。在两项最新的三期临床试验中，研究人员测试了7.2 毫克的司美格鲁肽剂量，而目前已获批的最高剂量为2.4毫克。 高剂量方案现可观增量，但疗效仍逊于礼来 虽然在最高效力上未能领先，但新的高剂量选择仍被视为具有临床意义。 格拉斯哥大学代谢医学教授Naveed Sattar指出，这种"渐进式"的益处在临床上仍具重要意义，特别是考虑到礼来高剂量替西帕肽在某些地区的价 格已大幅上涨。他认为： 诺和诺德公司日前公布了一项临床试验结果，其备受关注的司美格鲁肽（Semaglutide）在将剂量提高至三倍后，显示出更显著的减重效果。 安全性可控但副作用随剂量上升 疗效提升的同时，副作用的发生率也相应增加。试 ...

Eli Lilly has seen weakness in its stock price year to date. I think it's a short-term problem.It's not often that something as influential as an effective weight loss drug comes on the market. Eli Lilly (LLY -0.20%) has that product. They also have a leading treatment for diabetes and a burgeoning treatment for Alzheimer's. These multiple treatment avenues have the company set to rake in quite a bit of money as long as they don't screw it up.My general take here is that the remarkable revenue growth we saw ...

整理 | GLP1减重宝典内容团队 总体来看，礼来在多靶点GLP-1药物研发方面保持领先。替尔泊肽是首个GLP-1/GIP双靶点激动剂，而Retatrutide则是首个同时作用于 GLP-1/GIP/GCG的三靶点激动剂。目前，Retatrutide已有多项三期研究在进行，包括肥胖和2型糖尿病治疗，此次新增的MASLD三期 临床进一步扩展了其适应症探索。同时，Retatrutide也在评估对慢性肾病（CKD）等疾病的潜在疗效。 2025年9月10日，礼来在Clinicaltrials.gov登记了替尔泊肽与Retatrutide用于MASLD的三期临床研究。该研究计划纳入4500名MASLD 患者，预计2030年完成初步结果。此次试验将同时评估替尔泊肽和Retatrutide在MASLD治疗中的有效性与安全性，主要观察指标为 MALO复合终点。 *本文仅 供医疗卫生专业人 士参考 版权声明：所有「GLP1减重宝典」的原创文章，转载须联系授权，并在文首/文末注明来源、作者、微信ID，否则减重宝典将向其追究法律责 任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题，敬请原作者联系我们。合作事宜，请 ...

新官上任三把火。在履新诺和诺德（NVO.US）CEO一个月后，马齐亚尔·迈克·杜斯特达（Maziar Mike Doustdar，下称"杜麦克"）将第一把火对准了内部 组织架构。 9月10日，诺和诺德宣布将进行大规模重组，计划在全球裁员约9000人。这一改革旨在精简组织架构，提高决策速度，并将资源重新配置，以促进公司在 糖尿病和肥胖症领域的增长。 杜麦克对外表示，"我们的市场正在发生变化，尤其是在肥胖领域，其竞争更加激烈，消费者驱动力也更强。我们的公司也必须随之发展。这意味着我们 要培养一种更加以绩效为导向的文化，更有效地部署我们的资源，并将投资优先分配到最具影响力的地方——我们的领先治疗领域。" 诺和诺德指出，节省下来的资金将用于糖尿病和肥胖症领域的增长机会，包括商业执行计划和研发项目。 诺和诺德刀刃向内，是GLP-1领域竞争加剧的必然结果。2025年以来，GLP-1市场格局加速演变，从临床疗效到剂型创新，再到适应症拓展，诺和诺德和 礼来制药（LLY.US）的交锋已然进入"全方位对抗"阶段。其中，新药临床疗效的比拼，仍是双方缠斗的核心焦点。 9月1日，诺和诺德在2025年欧洲心脏病学会（ESC）年会上公布了 ...

Group 1: Eli Lilly (NYSE: LLY) - Eli Lilly is positioned as a key player in the weight-loss and diabetes treatment market, with significant sales growth driven by its drugs Mounjaro and Zepbound [2] - The company benefits from a defensive sector positioning, as healthcare spending remains resilient during economic downturns [3] - Despite its potential, Eli Lilly's stock has shown volatility in 2025, dropping 3% year-to-date to trade at $755 [3] Group 2: Broadcom (NASDAQ: AVGO) - Broadcom is a major player in the artificial intelligence and cloud infrastructure sectors, with its chips powering essential networking and wireless systems [5] - The stock has gained 55% year-to-date, trading at $359, reflecting its resilience in 2025 [5] - Broadcom's $69 billion acquisition of VMware diversifies its revenue streams and enhances its cash flow, appealing to income-seeking investors [7] - Long-term demand drivers from AI and data centers provide Broadcom with a solid growth outlook for 2025 and beyond, despite integration risks and semiconductor cyclicality [8]